NKT Cell-Based Immunotherapy for Non-Small-Cell Lung Cancer
Keywords:
NKT cells, Immunotherapy, Non-small cell lung cancer, Dendritic cellsAbstract
Invariant natural killer T (iNKT) cells are a unique lymphocyte subpopulation that possesses an invariant T cell receptor (TCR) and recognize glycolipid antigens, such as α-galactosylceramide (αGalCer), presenting on CD1d. Activated iNKT cells show a direct and indirect antitumor effect by producing effector molecules and cytokines that activate other immune cells, including NK cells and cytotoxic T cells. We are currently focusing on the development of immunotherapy targeting iNKT cells and have conducted early phase clinical trials for non-small cell lung cancer (NSCLC). Previous clinical studies have shown that the intravenous injection of α GalCer-pulsed dendritic cells (DCs) induced the activation of endogenous iNKT cells and iNKT celldependent responses. Furthermore, an increase in the number of IFN-γ- producing cells among peripheral blood mononuclear cells has been shown to be associated with prolonged survival. A dramatic infiltration of iNKT cells in the tumor microenvironment was also observed after the injection of αGalCerpulsed DCs. Based on these results, Phase Ⅱ clinical trials of αGalCerpulsed DCs for NSCLC were designed as Advanced Medical Technology and approved by the Japanese Ministry of Health, Labor, and Welfare. Patients with advanced or recurrent NSCLC who had received first-line chemotherapy underwent intravenous injections of αGalCer-pulsed DCs. αGalCer pulsed DCs were found to be well-tolerated and prolonged overall survival. We also discuss future potential combination therapies of iNKT cell-based immunotherapy to achieve enhanced antitumor activity and provide better treatment options for patients with advanced NSCLC.
References
Takami M, Ihara F, Motohashi S, 2018, Clinical Application of iNKT Cell-Mediated Anti-Tumor Activity Against Lung Cancer and Head and Neck Cancer. Front Immunol, 9: 2021.
Kawano T, Cui J, Koezuka Y, et al., 1997, CD1d-Restricted and TCR-Mediated Activation of Vα14 NKT cells by Glycosylceramides. Science, 278: 1626–1629.
Bray F, Ferlay J, Soerjomataram I, et al., 2018, Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 68: 394–424.
Cancer Research Foundation. Cancer Statistics ‘18. Cancer Statistics Editorial Board, 2018, Tokyo.
Ishikawa E, Motohashi S, Ishikawa A, et al., 2005, Dendritic Cell Maturation by CD11c-T Cells and Valpha24+ Natural Killer T-Cell Activation by Alpha-Galactosylceramide. Int J Cancer, 117: 265–273.
Ishikawa A, Motohashi S, Ishikawa E, et al., 2005, A Phase Ⅰ Study of α-Galactosylceramide (KRN7000)-Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer. Clin Cancer Res, 11: 1910–1917.
Motohashi S, Nagato K, Kunii N, et al., 2009, A Phase Ⅰ–Ⅱ Study of α-Galactosylceramide-Pulsed IL-2/GM-CSFCultured Peripheral Blood Mononuclear Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer. J Immunol, 182: 2492–2501.
Shepherd FA, Dancey J, Ramlau R, et al., 2000, Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients with Non-Small-Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy. J Clin Oncol, 18: 2095–2103.
Herbst RS, Baas P, Kim DW, et al., 2016, Pembrolizumab Versus Docetaxel for Previously treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. Lancet, 387: 1540–1550.
Motohashi S, Ishikawa A, Ishikawa E, et al., 2006, A Phase Ⅰ Study of in vitro Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer. Clin Cancer Res, 12: 6079–6086.
Motohashi S, Nakayama T, 2008, Clinical Applications of Natural Killer T Cell-Based Immunotherapy for Cancer. Cancer Sci, 99: 638–645.
Nagato K, Motohashi S, Ishibashi F, et al., 2012, Accumulation of Activated Invariant Natural Killer T Cells in the Tumor Microenvironment after α-Galactosylceramide-Pulsed Antigen Presenting Cells. J Clin Immunol, 32: 1071–1081.
Antonia SJ, Villegas A, Daniel D, et al., 2017, Durvalumab after Chemoradiotherapy in Stage Ⅲ Non-Small-Cell Lung Cancer. N Engl J Med, 377: 1919–1929.
Paz-Ares L, Luft A, Vicente D, et al., 2018, Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med, 379: 2040–2051.
Mok TSK, Wu YL, Kudaba I, et al., 2019, Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1- Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. Lancet, 393: 1819–1830.
Forde PM, Chaft JE, Smith KN, et al., 2018, Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med, 378: 1976–1986.
Kamata T, Suzuki A, Mise N, et al., 2016, Blockade of Programmed Death-1 / Programmed Death Ligand Pathway Enhances the Antitumor Immunity of Human Invariant Natural Killer T Cells. Cancer Immunol Immunother, 65: 1477–1489.
